Journal Club

Androgen-Deprivation Therapy and Metabolic Syndrome in Men With Prostate Cancer

Joanne M. Harrington

Dawn C. Schwenke

Dana R. Epstein

Donald E. Bailey
prostate cancer, androgen-deprivation therapy, metabolic syndrome
ONF 2013, 41(1), 21-29. DOI: 10.1188/14.ONF.21-29

Purpose/Objectives: To examine the trajectory of changes in body composition and metabolic profile in men who receive androgen-deprivation therapy (ADT) for prostate cancer.

Design: Prospective longitudinal design with repeated measures.

Setting: Urban medical center in the southwestern United States.

Sample: 55 men starting radiation therapy for prostate cancer.

Methods: Changes in the parameters of metabolic syndrome were estimated with ADT (n = 31) and non-ADT (n = 24) groups by repeated-measures analysis of variance implemented by general linear mixed-effects models. Models included interactions between groups and follow-up time to test differences between the groups.

Main Research Variables: Body composition and metabolic variables.

Findings: The ADT group demonstrated a transient increase in waist circumference at the nine-month time point and significant changes in measures of insulin resistance were noted at the three month point. Values for diastolic and systolic blood pressure, plasma glucose, high-density lipoprotein, and triglycerides were not altered for either group. Differences in metabolic variables or measures of body composition did not differ significantly between the groups.

Conclusions: The findings demonstrate the development of insulin resistance in men receiving ADT as early as three months after starting ADT.

Implications for Nursing: Addressing survivorship concerns can lead to the development of nursing interventions designed to reduce adverse effects associated with ADT.

Jump to a section


    Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., … Smith, S.C. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644
    Alberti, K.G., Zimmet, P., & Shaw, J. (2005). The metabolic syndrome—A new worldwide definition. Lancet, 366, 1059-1061.
    Alibhai, S.M., Duong-Hua, M., Sutradhar, R., Fleshner, N.E., Warde, P., Cheung, A.M., & Paszat, L.F. (2009). Impact of androgen deprivation therapy on cardiovascular disease and diabetes. Journal of Clinical Oncology, 27, 3452-3458. doi:10.1200/JCO.2008.20.0923
    Basaria, S., Lieb, J., Tang, A.M., DeWeese, T., Carducci, M., Eisenberger, M., & Dobs, A.S. (2002). Long-term effects of androgen deprivation therapy in prostate cancer. Clinical Endocrinology, 56, 779-786.
    Basaria, S., Muller, D.C., Carducci, M.A., Egan, J., & Dobs, A.S. (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer, 106, 581-587.
    Braga-Basaria, M., Dobs, A.S., Muller, D.D., Carducci, M.A., John, M., Egan, J., & Basaria, S. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology, 24, 3979-3983.
    Choong, K., & Basaria, S. (2010). Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male, 13, 1-9.
    Cleffi, S., Neto, A.S., Reis, L.O., Maia, P., Fonseca, F., Wroclawski, M.L., … Tobias-Machado, M. (2011). Androgen deprivation therapy and morbid obesity: Do they share cardiovascular risk through metabolic syndrome? Actas Urologicas Espanolas, 35, 259-265.
    Denis, L.J., & Griffiths, K. (2000). Endocrine treatment in prostate cancer. Seminars in Surgical Oncology, 18, 52-74.
    Dockery, F., Bulpitt, C.J., Agarwal, S., Donaldson, M., & Rajkumar, C. (2003). Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science, 104, 195-201.
    Haffner, S.M. (2006). The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease. American Journal of Cardiology, 97, 3A-11A. doi:10.1016/j.amjcard.2005.11.010
    Haidar, A., Yassin, A., Saad, F., & Shabsigh, R. (2007). Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male, 10, 189-196.
    Higano, C. (2012). Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 30, 3720-3725. doi:10.1200/JCO.2012.418509
    Keating, N.L., O'Malley, A.J., & Smith, M.R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24, 4448-4456. doi:10.1200/JCO.2006.06.2497
    Lage, M.J., Barber, B.L., & Markus, R.A. (2007). Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology, 70, 1104-1108. doi:10.1016/jurology.2007.08.012
    Lepor, H., & Shore, N.D. (2012). LHRH agonists for the treatment of prostate cancer: 2012. Reviews in Urology, 14, 1-12.
    Levine, G.N., D'Amico, A.V., Berger, P., Clark, P.E., Eckel, R.H., Keating, N.L., … Zakai, N. (2010). Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA: A Cancer Journal for Clinicians, 60, 194-201. doi:10.3322/caac.20061
    Myklak, K., & Wilson, S. (2011). An update on the changing indications for androgen deprivation therapy for prostate cancer. Prostate Cancer, 2011, 1-8. doi:10.1155/2011/419174
    Ness-Abramof, R., & Apovian, C.M. (2008). Waist circumference measurement in clinical practice. Nutrition in Clinical Practice, 23, 397-404. doi:10.1177/0884533608321700
    Nobes, J.P., Langley, S.E., & Laing, R.W. (2009). Metabolic syndrome and prostate cancer: A review. Clinical Oncology, 21, 1-9. doi:10.1016/j.clon.2008.11.013
    Quon, H., & Loblaw, D.A. (2010). Androgen deprivation therapy for prostate cancer—Review of indications in 2010. Current Oncology, 17(Suppl. 2), S38-S44.
    Rashid, M.H., & Chaudhary, U.B. (2004). Intermittent androgen deprivation therapy for prostate cancer. Oncologist, 9, 295-301.
    Saylor, P.J., & Smith, M.R. (2009). Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology, 181, 1998-2008. doi:10.1016.j.juro.2009.01.047
    Saylor, P.J., & Smith, M.R. (2012). Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer. Journal of the National Comprehensive Cancer Network, 8, 211-222.
    Shahani, S., Braga-Basaria, M., & Basaria, S. (2008). Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 93, 2042-2049.
    Shahinian, V.B., Kuo, Y.F., Freeman, J.L., Orihuela, E., & Goodwin, J.S. (2005). Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate cancer. Cancer, 103, 1615-1624.
    Shuster, A., Patlas, M., Pinthus, J.H., & Mourtzakis, M. (2012). The clinical importance of visceral adiposity: A critical review of methods for visceral adipose tissue analysis. British Journal of Radiology, 85(1009), 1-10. doi:10.1259/bjr/38447238
    Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63, 11-30. doi:10.3322/caac.21166
    Smith, J.C., Bennett, S., Evans, L.M., Kynaston, H.G., Parmar, M., Mason, M.D., … Davies, J.S. (2001). The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Endocrinology and Metabolism, 86, 4261-4267.
    Smith, M.R. (2007). Androgen deprivation therapy for prostate cancer: New concepts and concerns. Current Opinion in Endocrinology, Diabetes, and Obesity, 14, 247-254.
    Smith, M.R., Finkelstein, J.S., McGovern, F.J., Zietman, A.L., Fallon, M.A., Schoenfeld, D.A., & Kantoff, P.W. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 87, 599-603.
    Smith, M.R., Lee, H., McGovern, F., Fallon, M.A., Goode, M., Zietman, A.L., & Finkelstein, J.S. (2008). Metabolic changes during gonadatropin-releasing hormone agonist therapy for prostate cancer. Cancer, 112, 2188-2194. doi:10.1002/cncr.23440
    Smith, M.R., Lee, H., & Nathan, D.M. (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1305-1308.
    Trujillo, M.E., & Scherer, P.E. (2005). Adiponectin—Journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. Journal of Internal Medicine, 257, 167-175. doi:10.1111/j.1365-2796.2004.01426.x
    Yannucci, J., Manola, J., Garnick, M.B., Bhat, G., & Bubley, G.J. (2006). The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. Journal of Urology, 176, 520-525.